Es el doctor Robert Malone el inventor de las vacunas Covid-19 de ARNm? Aquí están las patentes

Patentes del Dr. Malone de el.inventobdeblas vacunas que se usan en las vacunas

Pfizer yvMODERN Early Patents priority dates from 1989
The first patents:

• Lipid-mediated polynucleotide administration to deliver a biologically active peptide and to induce a cellular immune response (includes mRNA). P Felgner, JA Wolff, GH Rhodes, R Malone, D Carson. Assigned to Vical, Inc and licensed to Merck. No. 7,250,404, date of issue: 7/31/07 Cited in 105 articles. Priority Date: 3/21/1989.
• https://patents.google.com/patent/US20030032615A1/en

• Lipid-mediated polynucleotide administration to reduce likelihood of subject’s becoming infected (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc and licensed to Merck. US Pat. Ser. No. 6,867,195 B1. Date of issue: 3/15/05. Priority Date: 3/21/1989.

• Generation of an immune response to a pathogen (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc and licensed to Merck. US Pat. Ser. No. 6,710,035. Date of issue: 3/23/04. Citations: 39 articles. Priority Date: 3/21/1989.
• https://patents.google.com/patent/US6867195B1/en

• Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 6,673,776. Date of issue: 1/6/04. Priority Date: 3/21/1989.
• https://pubchem.ncbi.nlm.nih.gov/patent/6710035-B2US-

• Methods of delivering a physiologically active polypeptide to a mammal (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 6,413,942. Date of issue: 7/2/02. (cited in 150 articles). Priority Date: 3/21/1989.
• https://app.dimensions.ai/details/patent/US-6413942-B1

• Induction of a protective immune response in a mammal by injecting a DNA sequence (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, licensed to Merck. US Pat. Ser. No. 6,214,804, date of issue: 4/10/01. Cited in 360 articles. Priority Date: 3/21/1989.
• https://patents.google.com/patent/US6214804B1/en

• Induction of a protective immune response in a mammal by injecting a DNA sequence (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 5,589,466. Date of issue: 12/31/96. Cited in 899 articles. Priority Date: 3/21/1989.
• https://patents.google.com/patent/US5589466A/en

============================

INTERVIEW WITJ DR. ROBERT MALONE, MD & SCIENTIST,  MR STEVE KIRSCH, ENGINEER INVENTOR, AND DR. BRET WEINSTEIN, PHD IN BIOLOGY SPECIALIZED IN EVOLUTION AND IMMUNO-BIOLOGY. 

Below are some of the descriptions of the invention taken from the above patents – priority date 1989.

• Generation of antibodies through lipid mediated DNA delivery (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 5,703,055. Date of issue: 12/30/97. Cited in 419 articles. Priority Date: 3/21/1989.
• https://patents.google.com/patent/US5703055A/en

Source: https://t.me/RWMaloneMD/1230

Some of Doctor Robert Malon papers and other patents on this subject area (1988-2000).

• A novel approach to study packaging of retroviral RNA by RNA transfection (Abstract). RW Malone, P. Felgner, I. Verma. RNA Tumor Viruses, May 17-18, 1988. Cold Spring Harbor (the first in a series of papers/abstracts on RNA transfection). https://www.rwmalonemd.com/s/J-A-Novel-Approach-to-Study-Packagnng-Ret-RNA-by-RNA-Tran-Malone-ColdSpringHarborpdf.pdf
•  
• mRNA Transfection of cultured eukaryotic cells and embryos using cationic liposomes. Malone RW. Focus. 1989; 11:61-8
• https://www.rwmalonemd.com/s/KFocusmRNATransfectofCulturedEukCellembryos1989Data198820210212.pdf
•  
• The SALK patent that was filed with the USPTO on 3/21/1989. Note that the cover letter hides this – and says it was filed on 3/29/89 – the sane date as all the VICAL patents, showing that there was collusion. WRITTEN BY DR. MALONE IN 1988.
•  
• THE VERY FIRST mRNA VACCINE EXPERIMENTAL DATA 1990 (from Vical to patent office) https://www.rwmalonemd.com/s/First-mRNA-vaccination-data-March-21-1990.pdf

• Cationic liposome-mediated RNA transfection. Malone RW, Felgner PL, Verma IM. Proc Natl Acad Sci (PNAS) U S A. 1989;86(16):6077-81. Cited in 749 articles.
• https://www.rwmalonemd.com/s/vaccination-data-March-21-1990.pdfFirst-mRNA–
•  
• Direct gene transfer into mouse muscle in vivo. Wolff JA, Malone RW, et al. Science. 1990;247(4949 Pt 1):1465-8. Cited in 4,750 articles. Note that Robert was a student at Northwestern, and was never affiliated with University of Wisc.https://science.sciencemag.org/content/247/4949/1465
•  
• High levels of messenger RNA expression following cationic liposome mediated transfection tissue cultured cells. Malone R, Kumar R, Felgner P. NIH Conference: “Self-Cleaving RNA as an Anti-HIV Agent (abstract). Washington, DC June 1989
• .
• Cationic liposome-mediated RNA transfection. Dwarki VJ, Malone RW, Verma IM. Methods Enzymol. 1993;217:644-54. Cited in: 102 articles. https://pubmed.ncbi.nlm.nih.gov/7682647/
•  
• Delivery of exogenous DNA (includes mRNA) sequences in a mammal P Felgner, JA Wolff, GH Rhodes, R Malone, D Carson. Biotechnology Advances 1993: 15 (3-4), 763-763

For a deeper dive into the actual data, patent disclosures, meeting notes, lab books, etc, go to this webpage. https://rwmalonemdllc.com/mrna-vaccine-docs

Patents and papers – from the 1990s

• DNA vaccines for eliciting a mucosal immune response (includes mRNA). US Pat. Ser. No. 6,110,898. Inventors: RW Malone and Jill Glasspool Malone. Date of issue: 8/29/00. Cited in 40 articles. Priority Date: 1996.
• https://pubchem.ncbi.nlm.nih.gov/patent/US-6110898-A
•  
• Formulations and methods for generating active cytofectin: polynucleotide transfection complexes. Robert W Malone, et al. US Pat. Ser. No. 5,925,623 7/20/99.
• https://patents.google.com/patent/US5925623
•  
• Cationic Transport Reagents. US Pat. Ser. No. 5,892,071 Robert W Malone, et. al. issued 4/06/99.
• https://patents.justia.com/patent/5892071
•  
• Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin: polynucleotide transfection complexes. Robert W Malone, et. al. US Pat. Ser. No. 5,824,812 issued 10/20/98.
• https://patents.google.com/patent/US5824812
•  
• Cationic Transport Reagents. Robert W Malone, et. al. US Pat. Ser. No. 5,744,625 issued 4/28/98.
• https://patents.google.com/patent/US5744625A/en
•  
• Cationic Transport Reagents. Robert W Malone, et. al. US Pat. Ser. No. 5,527,928, date of issue: 6/18/96.
• https://patents.google.com/patent/US5527928A/en
•  
• Marked enhancement of macaque respiratory tissue transfection by aurintricarboxylic acid. Glasspool-Malone J, …, Malone RW. Gene Med. 2002;4(3):323-2.
• https://www.liebertpub.com/doi/abs/10.1089/10430349950017707?journalCode=hum
•  
• Enhancing direct in vivo transfection with nuclease inhibitors and pulsed electrical fields. Glasspool-Malone J, Malone RW. In Gene Therapy Methods: Methods Enzymol. 2002;346:72-91 https://pubmed.ncbi.nlm.nih.gov/11883098/
•  
• Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Drabick JJ, Glasspool-Malone J, …, Malone RW. Mol Ther. 2001;3(2):249-55. Cited in 192 articles.
• https://pubmed.ncbi.nlm.nih.gov/11237682/
•  
• Theory and in vivo application of electroporative gene delivery. Somiari S, Glasspool-Malone J, … Malone RW. Mol Ther. 2000;2(3):178-87. Cited in 345 articles. https://pubmed.ncbi.nlm.nih.gov/11237682/
•  
• Efficient nonviral cutaneous transfection. Glasspool-Malone J, …, Malone RW. Mol Ther. 2000;2(2):140-6. Cited in 138 articles.
• https://www.sciencedirect.com/science/article/pii/S1525001600901072
•  
• Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy. Berlyn KA, …, Malone RW J Biotechnol. 1999;73(2-3):155-79
• https://pubmed.ncbi.nlm.nih.gov/10486925/
•  
• Models of Cationic Liposome Mediated Transfection. Gene Therapy and Molecular Biology. Ahearn A, Malone RW. Vol 4. Gene Therapy and Molecular Biology 1999;4
• http://gtmb.org/volumes/Vol4/_14FC%20MALONE%20159-170.pdf
•  
• Cationic lipid-mediated gene delivery to murine lung: correlation of lipid hydration with in vivo transfection activity. Bennett MJ, …, Malone RW, Nantz MH. J Med Chem. 1997;40(25):4069-78
• https://pubs.acs.org/doi/10.1021/jm970155q
•  
• Considerations for the design of improved cationic amphiphile-based transfection reagents. Bennett MJ, …, Malone RW. Journal of Liposome Research 1996;6(3):545-65
• https://www.tandfonline.com/doi/abs/10.3109/08982109609031136
•  
• Structural and functional analysis of cationic transfection lipids: the hydrophobic domain. Balasubramaniam RP, …, Malone RW. Gene Ther. 1996;3(2):163-72. cited in 172 articles.
• https://pubmed.ncbi.nlm.nih.gov/8867864/
•  
• A flexible approach to synthetic lipid ammonium salts for polynucleotide transfection. MJ Bennett, RW Malone, MH Nantz. Tetrahedron letters 36 (13), 2207-2210
• https://www.sciencedirect.com/science/article/abs/pii/004040399500276I

For the written history of the early events, by Dr. Jill Glasspool Malone https://static1.squarespace.com/static/617d909092cd2314e37ebe67/t/617de3cd04bffe53342539cb/1635640269719/Jill%27s+letter+about+RNA+vaccination+generic+v5+June2021.pdf

https://t.me/RWMaloneMD/1234

 

 

Source: https://t.me/RWMaloneMD/1233

 

 

,